Global InformationInvasive cribriform carcinoma of the breast information
 | This article's lead section may be too long. (July 2022) |
| Cribriform carcinoma of the breast | |
|---|---|
| Other names | Invasive cribriform carcinoma |
 | |
| Cribriform carcinoma of the breast showing a cribriform area | |
| Specialty | Oncology, Surgical oncology |
| Prognosis | excellent |
Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer that accounts for 0.3% to 0.6% of all carcinomas (i.e. cancers that develop from epithelial cells) in the breast.[1] It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands (lobules make the milk which the ducts channel to the breast's nipple). ICCB was first described by Dixon and colleagues in 1983 as a tumor that on microscopic histopathological inspection had a cribriform pattern,[2] i.e. a tissue pattern consisting of numerous "Swiss cheese"-like open spaces and/or sieve-like small holes (see adjacent Figure).[3] The latest edition (2019) of the World Health Organization (2019) termed these lesions invasive cribriform carcinomas indicating that by definition they must have a component that invades out of their ducts of origin into adjacent tissues. In situ ductal cancers (i.e. cancers localized entirely within their tissues of origin) that have a cribriform histopathology are regarded as belonging to the group of ductal carcinoma in situ tumors.[4]
Rarely, cancers with the histopathological cribriform pattern develop in other organs such as the prostate gland (termed invasive cribriform prostate cancer or cribriform prostate cancer),[5] salivary gland (termed cribriform adenocarcinoma of salivary glands),[6] sweat glands (termed primary cutaneous cribriform apocrine carcinoma),[7] thyroid gland (termed cribriform-morular thyroid carcinoma),[8] colon (termed cribriform colon cancer),[9][10] and lung (termed cribriform pattern in lung adenocarcinoma and considered to be a rare variant of acinar adenocrcinoma of the lung).[11] Here, the term invasive cribriform carcinoma of the breast rather than invasive cribriform carcinoma is used in order to clearly distinguish it from these other cribriform carcinomas.
ICCB, while clearly a cancerous tumor that occurs predominantly in older females and in rare cases males, has many favorable clinical and pathological features including a low rate of metastasizing to distant tissues and an excellent prognosis.[12] Earlier editions of the World Health Organization divided ICCB into two forms, the "pure" form (sometimes termed "classical"), i.e. ICCB tumors that had >90% cribriform areas, and the "mixed" form, i.e. ICCB tumors that had >50% cribriform areas with the remaining areas having a tubular histological pattern.[4] However, many earlier[1][11][13][14][15][16] and more recent[3][12][17] studies have regarded mixed ICCB as consisting of >50% cribriform areas with the remaining areas containing tubular or certain other histopathological patterns. The latter definition of mixed ICCB is used here.
- ^ a b Mo CH, Ackbarkhan Z, Gu YY, Chen G, Pang YY, Dang YW, Feng ZB (2017). "Invasive cribriform carcinoma of the breast: a clinicopathological analysis of 12 cases with review of literature". International Journal of Clinical and Experimental Pathology. 10 (9): 9917–9924. PMC 6965980. PMID 31966881.
- ^ Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ (July 1983). "Invasive cribriform carcinoma of the breast". Histopathology. 7 (4): 525–36. doi:10.1111/j.1365-2559.1983.tb02265.x. PMID 6884999. S2CID 6585654.
- ^ a b Erber R, Hartmann A (August 2020). "Histology of Luminal Breast Cancer". Breast Care (Basel, Switzerland). 15 (4): 327–336. doi:10.1159/000509025. PMC 7490665. PMID 32982642.
- ^ a b Cserni G (March 2020). "Histological type and typing of breast carcinomas and the WHO classification changes over time". Pathologica. 112 (1): 25–41. doi:10.32074/1591-951X-1-20. PMC 8138497. PMID 32202537.
- ^ Iczkowski KA, van Leenders GJ, Tarima S, Wu R, Van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Ro JY, Samaratunga H, Delahunt B, Srigley J, Varma M, Tsuzuki T, Egevad L (June 2021). "Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts". Annals of Diagnostic Pathology. 52: 151733. doi:10.1016/j.anndiagpath.2021.151733. PMID 33780691. S2CID 232420551.
- ^ Skálová A, Hyrcza MD, Leivo I (March 2022). "Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands". Head and Neck Pathology. 16 (1): 40–53. doi:10.1007/s12105-022-01420-1. PMC 9018948. PMID 35312980.
- ^ Davis A, Khachemoune A (February 2022). "Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma". Archives of Dermatological Research. 315 (1): 7–16. doi:10.1007/s00403-022-02323-5. PMID 35124722. S2CID 246558023.
- ^ Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O (March 2022). "Overview of the 2022 WHO Classification of Thyroid Neoplasms". Endocrine Pathology. 33 (1): 27–63. doi:10.1007/s12022-022-09707-3. PMID 35288841. S2CID 247440666.
- ^ Taylor AS, Liu N, Fang JM, Panarelli N, Zhao L, Cheng J, Gopal P, Hammer S, Sun J, Appelman H, Westerhoff M (July 2022). "Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability". Journal of Clinical Pathology. 75 (7): 483–487. doi:10.1136/jclinpath-2021-207485. PMID 33782192. S2CID 232420622.
- ^ Carraro DM, Elias EV, Andrade VP (February 2014). "Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression". Bioscience Reports. 34 (1). doi:10.1042/BSR20130077. PMC 3894794. PMID 27919043.
- ^ a b Branca G, Ieni A, Barresi V, Tuccari G, Caruso RA (March 2017). "An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance". Oncology Reviews. 11 (1): 317. doi:10.4081/oncol.2017.317. PMC 5364999. PMID 28382188.
- ^ a b Liu J, Zheng X, Han Z, Lin S, Han H, Xu C (February 2021). "Clinical characteristics and overall survival prognostic nomogram for invasive cribriform carcinoma of breast: a SEER population-based analysis". BMC Cancer. 21 (1): 168. doi:10.1186/s12885-021-07895-5. PMC 7887783. PMID 33593316.
- ^ Cong Y, Qiao G, Zou H, Lin J, Wang X, Li X, Li Y, Zhu S (April 2015). "Invasive cribriform carcinoma of the breast: A report of nine cases and a review of the literature". Oncology Letters. 9 (4): 1753–1758. doi:10.3892/ol.2015.2972. PMC 4356388. PMID 25789036.
- ^ Zhang W, Zhang T, Lin Z, Zhang X, Liu F, Wang Y, Liu H, Yang Y, Niu Y (2013). "Invasive cribriform carcinoma in a Chinese population: comparison with low-grade invasive ductal carcinoma-not otherwise specified". International Journal of Clinical and Experimental Pathology. 6 (3): 445–57. PMC 3563205. PMID 23412348.
- ^ Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM (August 2015). "Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study". Medicine. 94 (31): e1309. doi:10.1097/MD.0000000000001309. PMC 4616584. PMID 26252312.
- ^ Yılmaz TU, Trabzonlu L, Güler SA, Baran MA, Pösteki G, Erçin C, Utkan Z (January 2018). "Characteristics of Special Type Breast Tumors in Our Center". European Journal of Breast Health. 14 (1): 17–22. doi:10.5152/ejbh.2017.3219. PMC 5758058. PMID 29322114.
- ^ Demir S, Sezgin G, Sari AA, Kucukzeybek BB, Yigit S, Etit D, Yazici A, Kucukzeybek Y (October 2021). "Clinicopathological analysis of invasive cribriform carcinoma of the breast, with review of the literature". Annals of Diagnostic Pathology. 54: 151794. doi:10.1016/j.anndiagpath.2021.151794. PMID 34325338.